In this issue:
Timing for leucovorin rescue after high-dose MTX in NHL
Azacitidine + venetoclax in previously untreated AML
Allogeneic CAR T-cells for R/R B-cell ALL after alloHSCT
Zanubrutinib for R/R mantle cell lymphoma
First-line rituximab biosimilar CT-P10 + CHOP for DLBCL
Bosutinib for pre-treated chronic phase CML
Selinexor in MDS or oligoblastic AML refractory to hypomethylating agents
Sorafenib maintenance in FLT3-ITD AML undergoing alloHSCT
Intrathecal triple therapy vs intrathecal MTX for high-risk
B-lymphoblastic leukaemia MRD assessment in peripheral blood informs surveillance in childhood AML
Please login below to download this issue (PDF)